Literature DB >> 11300719

Alterations in cortical and basal ganglia levels of opioid receptor binding in a rat model of l-DOPA-induced dyskinesia.

P A Johansson1, M Andersson, K E Andersson, M A Cenci.   

Abstract

Opioid receptor-binding autoradiography was used as a way to map sites of altered opioid transmission in a rat model of l-DOPA-induced dyskinesia. Rats with unilateral 6-hydroxydopamine lesions of the nigrostriatal pathways sustained a 3-week treatment with l-DOPA (6 mg/kg/day, combined with 12 mg/kg/day benserazide), causing about half of them to develop dyskinetic-like movements on the side of the body contralateral to the lesion. Autoradiographic analysis of mu-, delta-, and kappa-opioid binding sites was carried out in the caudate-putamen (CPu), the globus pallidus (GP), the substantia nigra (SN), the primary motor area, and the premotor-cingulate cortex. The dopamine-denervating lesion alone caused an ipsilateral reduction in opioid radioligand binding in the CPu, GP, and SN, but not in the cerebral cortex. Chronic l-DOPA treatment affected opioid receptor binding in both the basal ganglia and the cerebral cortex, producing changes that were both structure- and receptor-type specific, and closely related to the motor response elicited by the treatment. In the basal ganglia, the most clear-cut differences between dyskinetic and nondyskinetic rats pertained to kappa opioid sites. On the lesioned side, both striatal and nigral levels of kappa binding densities were significantly lower in the dyskinetic group, showing a negative correlation with the rats' dyskinesia scores on one hand and with the striatal expression of opioid precursor mRNAs on the other hand. In the cerebral cortex, levels of mu and delta binding site densities were bilaterally elevated in the dyskinetic group, whereas kappa radioligand binding was specifically increased in the nondyskinetic cases and showed a negative correlation with the rats' dyskinesia scores. These data demonstrate that bilateral changes in cortical opioid transmission are closely associated with l-DOPA-induced dyskinesia in the rat. Moreover, the fact that dyskinetic and nondyskinetic animals often show opposite changes in opioid radioligand binding suggests that the motor response to l-DOPA is determined, at least in part, by compensatory adjustments of brain opioid receptors. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11300719     DOI: 10.1006/nbdi.2000.0372

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  18 in total

1.  Enhanced striatal cholinergic neuronal activity mediates L-DOPA-induced dyskinesia in parkinsonian mice.

Authors:  Yunmin Ding; Lisa Won; Jonathan P Britt; Sean Austin O Lim; Daniel S McGehee; Un Jung Kang
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-27       Impact factor: 11.205

2.  Dual κ-agonist/μ-antagonist opioid receptor modulation reduces levodopa-induced dyskinesia and corrects dysregulated striatal changes in the nonhuman primate model of Parkinson disease.

Authors:  Lisa F Potts; Eun S Park; Jong-Min Woo; Bhagya L Dyavar Shetty; Arun Singh; Steven P Braithwaite; Michael Voronkov; Stella M Papa; M Maral Mouradian
Journal:  Ann Neurol       Date:  2015-03-27       Impact factor: 10.422

3.  Striatal Nurr1, but not FosB expression links a levodopa-induced dyskinesia phenotype to genotype in Fisher 344 vs. Lewis hemiparkinsonian rats.

Authors:  Kathy Steece-Collier; Timothy J Collier; Jack W Lipton; Jennifer A Stancati; Mary E Winn; Allyson Cole-Strauss; Rhyomi Sellnow; Melissa M Conti; Natosha M Mercado; Eduardo A Nillni; Caryl E Sortwell; Fredric P Manfredsson; Christopher Bishop
Journal:  Exp Neurol       Date:  2020-05-05       Impact factor: 5.330

4.  The selective kappa-opioid receptor agonist U50,488 reduces L-dopa-induced dyskinesias but worsens parkinsonism in MPTP-treated primates.

Authors:  Heather Cox; Daniel M Togasaki; Li Chen; J William Langston; Donato A Di Monte; Maryka Quik
Journal:  Exp Neurol       Date:  2007-02-03       Impact factor: 5.330

5.  Maladaptive striatal plasticity in L-DOPA-induced dyskinesia.

Authors:  M Angela Cenci; Christine Konradi
Journal:  Prog Brain Res       Date:  2010       Impact factor: 2.453

6.  Transcriptome analysis in a rat model of L-DOPA-induced dyskinesia.

Authors:  Christine Konradi; Jenny E Westin; Manolo Carta; Molly E Eaton; Katarzyna Kuter; Andrzej Dekundy; Martin Lundblad; M Angela Cenci
Journal:  Neurobiol Dis       Date:  2004-11       Impact factor: 5.996

7.  µ Opioid Receptor Agonism for L-DOPA-Induced Dyskinesia in Parkinson's Disease.

Authors:  Erwan Bezard; Qin Li; Heather Hulme; Elva Fridjonsdottir; Anna Nilsson; Elsa Pioli; Per E Andren; Alan R Crossman
Journal:  J Neurosci       Date:  2020-07-20       Impact factor: 6.167

Review 8.  Priming for l-dopa-induced dyskinesia in Parkinson's disease: a feature inherent to the treatment or the disease?

Authors:  Agnès Nadjar; Charles R Gerfen; Erwan Bezard
Journal:  Prog Neurobiol       Date:  2008-09-30       Impact factor: 11.685

9.  Treatment of Levodopa-induced Dyskinesia.

Authors:  Jayaraman Rao
Journal:  Curr Treat Options Neurol       Date:  2007-05       Impact factor: 3.598

10.  Response of striosomal opioid signaling to dopamine depletion in 6-hydroxydopamine-lesioned rat model of Parkinson's disease: a potential compensatory role.

Authors:  Hidetaka Koizumi; Ryoma Morigaki; Shinya Okita; Shinji Nagahiro; Ryuji Kaji; Masanori Nakagawa; Satoshi Goto
Journal:  Front Cell Neurosci       Date:  2013-05-17       Impact factor: 5.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.